How much does a box of Pitobrutinib cost?

Pirtobrutinib, trade name Jaypirca, is an innovative targeted therapy drug developed by Eli Lilly and Company of the United States. It is primarily used to treat patients with mantle cell lymphoma (MCL) who have relapsed or been refractory to at least two systemic therapies, including BTK inhibitors.

Pittobrutinib blocks the growth and division of lymphoma cells by inhibiting Brutinib-sensitive kinase (BTK), a key molecule in the B cell receptor signaling pathway. This unique mechanism of action allowed pitobrutinib to perform well in clinical trials, not only extending patients' survival but also significantly improving their quality of life.

In addition to mantle cell lymphoma, pitobrutinib has also shown potential therapeutic efficacy against other types of B-cell lymphoma, such as chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). This further broadens the clinical application scope of pitobrutinib.

Pitobrutinib has a relatively high safety profile. Although some side effects may occur during treatment, such as fatigue, musculoskeletal pain, diarrhea, etc., these side effects are usually controllable and can be tolerated by most patients. However, patients still need to pay close attention to their physical condition when using pitobrutinib and report any discomfort or abnormal reactions to their doctor in a timely manner.

Pitobrutinib is not currently on the market in China. If domestic patients need this drug, they need to consider purchasing it overseas or contact overseas medical consulting companies through formal channels. According to people familiar with the matter, in overseas markets, there are two original and generic versions of pittobrutinib to choose from. Taking the original version on the US market as an example, the price of 50mg*30 tablets is about 100,000 yuan, while the generic version in Laos is relatively low-priced, about 4,500 yuan. To obtain more information about Pitobrutinib, it is recommended to consult a professional overseas medical consulting agency.